Research programme: lipocalin variants - Pieris Pharmaceuticals

Drug Profile

Research programme: lipocalin variants - Pieris Pharmaceuticals

Alternative Names: PRS-342; PRS-343

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Bispecific antibodies; Lipocalins
  • Mechanism of Action CD137 antigen antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Aug 2017 US FDA accepts IND for PRS 343 for Solid tumours for review
  • 09 Aug 2017 Pieris Pharmaceuticals plans a phase I trial for HER-2-positive Solid tumours for PRS 343 in USA
  • 05 Jul 2017 Pieris Pharmaceuticals files an IND application for PRS 343 with the US FDA in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top